Clinical Trial Update: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) [Phase 2]

View source ↗

Summary

Open-label extension study of ubenimex in pulmonary arterial hypertension (WHO Group 1) completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• ubenimex (ubenimex)

Snippet

Sponsor: Eiger BioPharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2023-01-18